New hope for rare blood disease: experimental drug targets AL amyloidosis
NCT ID NCT06158854
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 26 times
Summary
This study tests an experimental drug, etentamig (ABBV-383), in about 76 adults with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The drug aims to reduce these proteins by targeting the bone marrow cells that produce them. Participants receive the drug by infusion for up to 2 years, and researchers will monitor side effects and how well the disease is controlled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alexandra General Hospital /ID# 255542
RECRUITINGAthens, Attica, 11528, Greece
-
Atrium Health Levine Cancer Institute /ID# 255074
RECRUITINGCharlotte, North Carolina, 28204, United States
-
Atrium Health Wake Forest Baptist Medical Center /ID# 255851
RECRUITINGWinston-Salem, North Carolina, 27157, United States
-
Boston Medical Center /ID# 255066
RECRUITINGBoston, Massachusetts, 02118, United States
-
Box Hill Hospital /ID# 255199
RECRUITINGBox Hill, Victoria, 3128, Australia
-
CHU Limoges - Dupuytren 1 /ID# 255370
RECRUITINGLimoges, Franche-Comte, 87042, France
-
CHU Toulouse - Hopital Rangueil /ID# 255377
RECRUITINGToulouse, Haute-Garonne, 31400, France
-
Columbia University Medical Center /ID# 255068
RECRUITINGNew York, New York, 10032-3729, United States
-
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 255654
RECRUITINGBologna, 40138, Italy
-
Icahn School of Medicine at Mount Sinai /ID# 255408
RECRUITINGNew York, New York, 10029, United States
-
Japanese Red Cross Medical Center /ID# 256083
RECRUITINGShibuya-ku, Tokyo, 150-8935, Japan
-
Kumamoto University Hospital /ID# 262579
RECRUITINGKumamoto, Kumamoto, 8608556, Japan
Contact Phone: •••-•••-••••
-
Mayo Clinic - Rochester /ID# 255258
RECRUITINGRochester, Minnesota, 55905-0001, United States
-
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 255073
RECRUITINGNew York, New York, 10065-6007, United States
-
Nagoya City University Hospital /ID# 256086
RECRUITINGNagoya, Aichi-ken, 467-8602, Japan
-
Oregon Medical Research Center /ID# 255119
RECRUITINGPortland, Oregon, 97239, United States
-
Princess Alexandra Hospital /ID# 255202
RECRUITINGWoolloongabba, Queensland, 4102, Australia
-
Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856
RECRUITINGMiami, Florida, 33136, United States
-
University of Washington /ID# 261581
RECRUITINGSeattle, Washington, 98109, United States
-
Westmead Hospital /ID# 255200
RECRUITINGWestmead, New South Wales, 2145, Australia
-
Wisconsin Medical Center /ID# 255836
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.